NDRA — ENDRA Life Sciences Inc
NASDAQ · Healthcare · Diagnostics & Research
$5.27
+$0.26 (+5.29%)
ENDRA Life Sciences Inc (NDRA) is a diagnostics & research company listed on NASDAQ. It is led by Alexander Y. Tokman, based in 3600 Green Court, Ann Arbor, MI, United States, 48105-1570, with about 21 employees. ENDRA Life Sciences Inc. develops technologies to improve the capabilities of clinical diagnostic ultrasound. The company is involved in the development of thermo-acoustic enhanced ultrasound technology that uses pulsed energy source comprising radio frequency to transmit energy deep into tissue and generate ultrasonic waves to create high-contrast images for use in the treatment of non-alcoholic fatty liver disease, as well as in tissue composition, temperature monitoring, vascular imaging, and tissue perfusion. ENDRA Life Sciences Inc. was incorporated in 2007 and is based in Ann Arbor, Michigan.
Net income was -$1.6M. NDRA currently screens at market cap $2.6M and trailing P/E 0.0.
Use this NDRA page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the NDRA quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the NDRA SEC filings page. Lician reads the product cache first so this HTML stays unique to ENDRA Life Sciences Inc even when a live quote feed is slow.
About ENDRA Life Sciences Inc
ENDRA Life Sciences Inc. develops technologies to improve the capabilities of clinical diagnostic ultrasound. The company is involved in the development of thermo-acoustic enhanced ultrasound technology that uses pulsed energy source comprising radio frequency to transmit energy deep into tissue and generate ultrasonic waves to create high-contrast images for use in the treatment of non-alcoholic fatty liver disease, as well as in tissue composition, temperature monitoring, vascular imaging, and tissue perfusion. ENDRA Life Sciences Inc. was incorporated in 2007 and is based in Ann Arbor, Michigan.
NDRA Key Statistics
Market Cap
$2.61M
Volume
9,848
Previous Close
$5.44
Day Range
$5.28 – $5.60
P/E Ratio
0.01
EPS
-$56.94
Revenue
$0.00
Net Income
-$11.51M
Gross Profit
$0.00
Free Cash Flow
$0.00
Employees
21
NDRA Financials
Annual income statement in USD. Latest reported periods first.
| Line | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross Profit | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Net Income | -$11.51M | -$10.06M | $13.18M | $11.23M |
| EPS (Diluted) | -$56.94 | -$2.77K | $0.00 | $0.00 |
Total Assets
$4.45M
Total Debt
$0.00
Shareholders' Equity
$0.00
Cash & Equivalents
$0.00
Operating Cash Flow
-$7.40M
Free Cash Flow
$0.00
ENDRA Life Sciences Inc Company Information
- Acting CEO & Chairman
- Alexander Y. Tokman
- Headquarters
- 3600 Green Court, Ann Arbor, MI, United States, 48105-1570
- Website
- endrainc.com
- Phone
- 734 335 0468
- IPO / Founded
- 2017-05-09
- Sector
- Healthcare
- Industry
- Diagnostics & Research